Decoy Therapeutics Inc.
DCOY
$5.15
-$0.29-5.33%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -124.52% | -0.22% | 21.05% | 37.54% | 55.55% |
| Total Depreciation and Amortization | 61.36% | 0.00% | -50.56% | -53.68% | -56.44% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3,089.77% | -57.64% | -65.83% | -56.59% | -58.21% |
| Change in Net Operating Assets | -235.48% | 171.24% | 145.77% | 137.06% | 179.75% |
| Cash from Operations | -6.67% | 16.26% | 46.10% | 60.54% | 64.77% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 52.46% | 37.84% | 30.13% | 11.09% | -66.11% |
| Issuance of Common Stock | 724.68% | 326.90% | 2,259.64% | -67.36% | -78.26% |
| Repurchase of Common Stock | -- | -- | 71.12% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,064.06% | 517.43% | 386.04% | -70.99% | -84.04% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 338.80% | 135.51% | 70.03% | 47.46% | 44.17% |